Umbilical cord mesenchymal stem cells limit post-stroke infection

Jianbang Han
Zhujiang Hospital

Yu Xie
Zhujiang Hospital

Zhiming Feng
Zhujiang Hospital

Haitao Sun
Zhujiang Hospital

Feng Li
Zhujiang Hospital

Qian Ouyang
Zhujiang Hospital

Zhongfei Zhang
Zhujiang Hospital

Xiaoxiong Zou
Zhujiang Hospital

Yingqian Cai
Zhujiang Hospital

Yuxi Zou
Zhujiang Hospital

Yanping Tang
Zhujiang Hospital

Xiaodan JIANG (jiangxd@smu.edu.cn)
Southern Medical University  https://orcid.org/0000-0002-6211-7170

Research

Keywords: Umbilical cord mesenchymal stem cells, post-stroke infection, platelet

DOI: https://doi.org/10.21203/rs.3.rs-218526/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Brain ischemia leads to excessive infiltration of clusters of CD8\(^+\) T and natural killer (NK) cells in the brain, which aggravate ischemic brain injury. Acute ischemic stroke also has a negative impact on the antibacterial immune response, leading to stroke-induced immunodepression and infection. Umbilical cord mesenchymal stem cell (ucMSC) have an immunosuppressive function. Therefore, we aimed to determine whether ucMSC treatment alleviates the excessive infiltration of CD8\(^+\) T and NK cells. We also investigated significant concerns that ucMSC treatment might suppress antimicrobial immunity, leading to an increased risk of infection.

Methods

After middle cerebral artery occlusion, stroke and post-stroke infective mice received intravenous injection of ucMSC. We performed haematoxylin and eosin staining of organs and assessed the Modified Neurological Severity Score (mNSS), the activated state of microglia, quantity and distribution of CD8 + T and NK cells. Changes of cytokines (IL-6, TNF-\(\alpha\), IL-10), and blood biochemical indexes were also detected. We then assessed autophagy and apoptosis of platelets, as well as mitochondrial membrane potential (MMP) and ATP levels. In vitro ucMSC was co-cultured with platelet and Escherichia coli, followed by detection of the E. coli growth curve.

Results

ucMSC treatment ameliorated the infiltration of CD8\(^+\) T and NK cells in the brain, reduced levels of proinflammatory cytokines, and increased anti-inflammatory cytokines. ucMSC treatment limit post-stroke infection and reduce the inflammatory injury of various organs induced by post-stroke infection, as well as ucMSC inhibit the growth of Escherichia coli in vivo and vitro. ucMSC treatment maintained autophagy, MMP, and the production of ATP, while inhibiting apoptosis of platelets in vivo.

Conclusions

Based on these findings, ucMSC may represent a potential and safe therapeutic option for stroke treatment by inhibiting brain injury and limiting post-stroke infection.

Introduction

Infectious complications—primarily pneumonia and urinary tract infection—are a leading cause of death in ischemic stroke patients[1, 2]. The impairment of immune responses after brain ischemia increases
susceptibility to infections[3, 4]. Excessive infiltration of cluster of differentiation (CD)8+ T cells or natural killer (NK) cells in the brain aggravates ischemic brain injury, while brain ischemia compromises NK cell-mediated immune defence in the periphery and can result in post-stroke infection[5–7]. In addition, the grade of immunoinflammatory activation could be related to pathogenesis of neuronal damage in ischemic stroke[8, 9]. For example, TNF-α and IL-6 express a higher level in plasma of acute ischemic stroke patients, which play a pivotal role in inflammatory processes that aggravate ischemic neural damage[10]. While mesenchymal stem cells (MSCs) have been shown to exert therapeutic effects following stroke[11], they inhibit the proliferation and effector functions of various immune cells, including T and B lymphocytes and NK cells[12–17]. It is currently unknown, however, whether ucMSCs also suppress antimicrobial immunity and thereby increase the risk of infection.

In our previous study, we detected no obvious signs of infection in mice with stroke with or without umbilical cord (uc)MSC treatment. In another study, however, we established a post-stroke infection model using the gram-positive intracellular bacteria Listeria monocytogenes[6] or Escherichia coli, and this decreased the number of platelets in mice, while ucMSC treatment reversed this change. Symptoms of infection were also alleviated when these mice were injected with ucMSC, suggesting their therapeutic potential against post-stroke infection. This potential was investigated further in the present study by examining the effects of ucMSC on platelets and post-stroke infection, as well as determining the underlying mechanisms for these effects.

**Methods**

**Animals**

C57BL6 mice were purchased from the Laboratory Animal Center of Southern Medical University and were maintained under standard laboratory conditions, with the temperature controlled at 24°C and with free access to a standard diet and sterile water. All animal procedures were performed in accordance with the guidelines and approval of the Animal Ethics Committee of Southern Medical University.

**Middle cerebral artery occlusion (MCAO) and post-stroke infection model**

Mice weighing 20–22 g (aged 7–8 weeks) were allowed free access to water but were fasted for 12 h to standardize glycaemic state. MCAO was performed under anaesthesia induced by intraperitoneal injection of pentobarbital (100 mg/kg). Body temperature was maintained at 37°C ± 0.5°C using a heating pad (RWD Life Science, Shenzhen, China). To induce MCAO, a 6−0 nylon suture (Covidien, Mansfield, MA, USA) with a round tip and silicon coating was inserted from the left external carotid artery into the middle cerebral artery. The success of the surgery was verified by monitoring surface cerebral blood flow using a laser Doppler flowmeter (Moor Instruments, Devon, UK). After 1 h, the occluding filament was gently withdrawn back into the common carotid artery to allow reperfusion. Mice in the sham group underwent a sham operation without suture insertion.
E. coli were cultured as previously described[18] and stored in 30% glycerol at −80°C until use. E. coli were grown in Luria-Bertani (LB) medium (10 g/l tryptone, 5 g/l yeast extract, and 171.1 mM NaCl). Growth was determined by measuring the optical density at 620 nm (OD$_{620}$) or by plating the cells on LB plates and counting viable cells. For infection, age-matched male mice were intravenously injected with $10^7$ colony forming units (CFU) of E. coli resuspended in 500 µl phosphate-buffered saline (PBS) immediately after sham or MCAO operation.

To determine the degree of infection, the mouse liver, lung, and brain were removed and homogenized in distilled water with 0.01% Triton X-100. The number of viable E. coli cells was counted after plating serial dilutions of organ homogenates and blood on LB plates and culturing overnight at 37°C.

**Assessment of neurological function and measurement of cerebral infarct area**

Neurological function was determined based on the Modified Neurological Severity Score (mNSS). The test was carried out by a blinded investigator before and 3 days after MCAO, as previously described[19]. The infarct areas of different experimental groups were measured in photomicrographs of methylthioninium chloride-stained tissue sections (5 sections/animal). Experiments were repeated five times.

**Hematoxylin and eosin (HE) staining, immunohistochemistry, immunofluorescence analysis and flow cytometry analysis**

At 24 h after MCAO or post-stroke infection, mice were anesthetized and transcardially perfused with 20 ml cold PBS and 20 ml of 4% paraformaldehyde in 0.1 M PBS. The brain, lung, liver, and spleen were removed, post-fixed, and embedded in paraffin. The tissue blocks were cut into 5-mm sections that were deparaffinized and stained with HE according to standard protocols.

CD8$^+$ T cells and NK cells in the brain and spleen were identified by immunofluorescence analysis and immunohistochemistry, as previously described. For the latter, brain and spleen tissue sections were incubated overnight at 4°C with primary antibodies against CD8 (ab25117) and natural cytotoxicity receptor (NCR) (ab199128),Iba1(ab5076),CD68(ab125212)(Abcam,Cambridge,MA,USA) respectively followed by processing with avidin-biotin-peroxidase (BosterBio, Wuhan, China). The sections were stained with diaminobenzidine, and nuclei were counterstained with hematoxylin.

For immunofluorescence, the specimens were first treated with anti-CD8 or -NCR antibody, followed by Alexa Fluor 594-conjugated secondary antibody (A0453; Beyotime Institute of Biotechnology, Shanghai, China). Immunofluorescence images were acquired with a confocal laser scanning microscope (TCS SP2; Leica Microsystems, Wetzlar, Germany).
Blood biochemical analysis

Mouse blood was collected via the angular vein under anaesthesia into an anticoagulant-containing tube. Biochemical analyses were performed at Southern Medical University Huayin Laboratory.

Enzyme-linked immunosorbent assay (ELISA)

Plasma was isolated by centrifugation of blood samples at 1500 rpm for 20 min. TNF-α, IL-6, IL-10 in the plasma were detected with ELISA kits (Cusabio, Wuhan, China) according to the manufacturer's instructions. Briefly, 100 µl of plasma was added to each well of a 96-well plate. After incubation for 2 h at 37°C, the plasma was removed, and the plates were sequentially incubated with biotin-conjugated primary antibody followed by horseradish peroxidase-conjugated secondary antibody for 1 h at 37°C, with three washes between each step. After adding the chromogenic substrate, the plates were incubated in the dark for 30 min at 37°C. The reaction was terminated, and the OD$_{450}$ was measured using an iMark microplate reader (Bio-Rad, Hercules, CA, USA).

Co-culture of bacteria and ucMSC

Platelets alone or in combination with ucMSC were inoculated with *E. coli* for 1, 2, 4, or 6 h. Bacterial growth was determined by measuring the OD$_{620}$.

Statistical analysis

Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Data are presented as the mean ± SD. The significance of differences between means was examined by Student's *t*-test or one-way analysis of variance. Results with *P* < 0.05 were considered significant.

Results

ucMSC decrease brain lesion size and improve neurological function after stroke

We evaluated the effect of ucMSC on stroke based on measurement of the lesion area and the mNSS in an MCAO mouse stroke model. mNSS scores (*P* < 0.05; Fig. 1A) as well as the lesion area (*P* < 0.05; Fig. 1B) were reduced in the ucMSC treatment group as compared to those of the MCAO group, suggesting that ucMSC exert therapeutic effects after stroke.

ucMSC inhibit immunological function after stroke

We next examined the immunomodulatory effects of ucMSC treatment on the post-stroke brain by examining the abundance of CD8$^+$ T cells and NK cells by immunohistochemistry and immunofluorescence analysis, as well as flow cytometric analysis. Both cell populations were diminished in mice treated with ucMSC as compared to that in the MCAO group (Fig. 2A–C). We detected the activated microglia by staining Iba1 and CD68 (activated microglia marker) after induction of MCAO. Iba1-
and CD68-positive cells were increased after MCAO, while ucMSC treatment decreased the Iba1-positive and CD68-positive cells (Fig. 2D). Additionally, the proportions of CD8+ T cells and NK cells were decreased in the spleen and peripheral blood after MCAO, but these changes were not abrogated in the MCAO + ucMSC group (Fig. 2D–G). Meanwhile, plasma levels of the pro-inflammatory cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-α were lower, whereas that of the anti-inflammatory cytokine IL-10 was higher, in ucMSC-treated mice as compared to levels in untreated MCAO mice, as determined by ELISA (Fig. 3A–C).

**ucMSC treatment mitigates infection after stroke and prevents organ damage**

HE staining of lung, liver, and spleen tissue sections as well as blood routine revealed no signs of infection in MCAO mice with or without ucMSC treatment(Fig. 4). To assess the effect of systemically administered ucMSC on post-stroke infection, MCAO mice with or without ucMSC treatment and E. coli infection were examined for the presence of bacteria in the brain, lung, liver, and spleen. Compared to the MCAO group, MCAO + ucMSC mice showed a lower bacterial burden in these organs, including a reduction in the size of the germinal centre of the spleen (Fig. 5E). During post-stroke infection, inflammatory cells infiltrated the lung, brain, and liver and caused cell and tissue damage; these effects were alleviated by ucMSC treatment. We also measured aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), and lactate dehydrogenase (LDH) levels in plasma and found that AST, ALT, CK and LDH were downregulated in the ucMSC treatment group as compared to levels in the MCAO group during the course of infection. Plasma TNF-α and IL-6 levels were also reduced, whereas IL-10 was upregulated by ucMSC treatment.

**ucMSC and platelets have synergistic antibacterial effect**

To investigate whether ucMSC have the ability of platelets to kill bacteria, ucMSC was co-cultured with *E. coli*. Finally, we found the growth of *E. coli* was inhibited in the presence of ucMSC (Fig. 9).

**Discussion**

Infection in the lungs and other organs are relatively common during the subacute stage of stroke and are associated with unfavourable outcomes[20]. Preventative antibiotic therapy does not influence functional outcomes in the overall population [21, 22]. Ischemic stroke negatively impacts the antibacterial immune response, leading to stroke-induced immunosuppression and infection[7, 23]. For example, brain ischemia can cause a reduction in NK cell numbers and response in the periphery via activation of the catecholaminergic system and hypothalamic-pituitary-adrenal axis, which can result in infectious complications [6]. In accordance with previous studies[24], we observed a decrease in the numbers of CD8+ T cells and NK cells in the spleen and peripheral blood after stroke, whereas more of these cells infiltrated the brain tissue, which could aggravate brain injury. MSCs(mesenchymal stem cells) have immunomodulatory activity and are therefore promising agents for cell-based therapies. MSCs regulate a variety of immune cells—for example, they inhibit the activation and proliferation of T cells and induce T
cell apoptosis while suppressing the differentiation and maturation of dendritic cells [25–29]. MSCs have also been shown to block NK cell activity [30–32]. In our study, we found that ucMSC reduced the number of CD8+ T cells and NK cells in brain tissue but not in the spleen or peripheral blood of mice following stroke, suggesting that ucMSC can prevent brain injury. Furthermore, plasma levels of the pro-inflammatory cytokines IL-6 and TNF-α were reduced, whereas that of the anti-inflammatory cytokine IL-10 was increased by ucMSC treatment, confirming that ucMSC induce immunosuppression [33].

One point of concern is whether ucMSC can increase the risk of infection after stroke by suppressing antimicrobial immunity. However, symptoms of post-stroke infection were alleviated in mice following ucMSC treatment, which not only inhibited the growth of bacteria in certain organs but also prevented tissue damage caused by bacteria and inflammatory factors. Post-stroke pneumonia is a major cause of death after stroke [34]. In our study, ucMSC treatment reduced haemorrhage, oedema, and cellularity in injured lung lobes caused by E. coli. So our results show that ucMSC play a protective role against post-stroke infection, but the underlying mechanisms were not completely clear. Some studies demonstrated MSC have anti-infection effect of is mediated in part from secretion of the antimicrobial peptide [35, 36], which may be one reason of ucMSC inhibiting the post-stroke infection. However, we also found ucMSC inhibit the apoptosis of platelets, as well as maintain the count of platelets after post-stroke infection.

In previous studies, platelets have been shown to inhibit bacterial growth by surrounding bacteria and secreting a high concentration of antimicrobial substances [37]. Platelets also activate some immune cell types to fight bacteria and work with Kupffer cells to eradicate blood-borne bacterial infection caused by Bacillus cereus and methicillin-resistant Staphylococcus aureus [38]. Moreover, they interact with neutrophils to form a neutrophil extracellular trap that sequesters bacteria [39]. However, platelets invariably show diminished function and numbers after severe infection. For example, patients with sepsis often exhibit thrombocytopenia, which is associated with poor prognosis [40–42]. The mitochondrial dysfunction in platelets observed in sepsis and bacterial infection can lead to apoptosis: Bcl-xL—an essential regulator of platelet survival—is upregulated in the platelets of sepsis patients [43, 44]. Autophagy is important for platelet functions, including haemostasis and thrombosis [45]. In our study, ucMSC treatment reversed the decrease in the autophagy marker LC3-II caused by MCAO and E. coli infection. Mitochondria are the main target of the intrinsic apoptosis pathway, and mitochondrial membrane depolarization serves as a marker of apoptosis [46]. ATP provided by mitochondria plays an important role in normal cellular functioning, including the response to physiological stress [47]. Thus, a decrease in ATP levels reflects platelet damage. In the present study, ucMSC treatment increased the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, while restoring MMP and ATP production in platelets. In vitro, ucMSC and platelets can synergistically inhibit the proliferation of Escherichia coli. So we conclude that ucMSC may play a protective role against post-stroke infection by restoring the count and the function of platelet.

Conclusions
These results suggest that ucMSC have the ability to modulate the function of CD8$^+$ T cells, NK cells. Our study serves as the basis for future studies and offers new insights into the mechanisms responsible for the beneficial effect of ucMSC transplantation in patients with stroke and post-stroke infection.

**Abbreviations**

ucMSC, umbilical cord mesenchymal stem cell; IL, interleukin; MCAO, middle cerebral artery occlusion; mNSS, modified neurological severity score; NK, natural killer cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; MMP, mitochondrial membrane potential; LB, Luria-Bertani

**Declarations**

**Ethics approval and consent to participate**

All experimental procedures and animal care were performed in accordance with the guidelines and approval of the Animal Ethics Committee of Southern Medical University and were conducted in accordance with the policy of the National Institutes of Health on the care and use of animal

**Consent for publication**

Not applicable.

**Availability of data and materials**

All the data and informations used and/or analyzed during the current study available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by grants from the Funds for the National Natural Science Foundation of China (NSFC) projects (No.81874077), Key Science and Technology Project of Guangdong (No. 2016B030230004), Key Projects of Health Collaborative Innovation of Guangzhou (No. 2018030400016), Guangdong Provincial Department of Education Key Project (No. Guangdong Research Letter (2018) 17) to Prof. Xiaodan Jiang.

**Author’s contributions**

JH, ZF, YX and XJ designed the experiments; HT S, FL, and Q OUYANG performed the experiments; ZZ performed data collection and analysis; X Z, YC, YZ and YT wrote the manuscript together; XJ guided this
study, revised the manuscript and provided financial support. All authors performed the final approval of the manuscript.

Acknowledgements

Not applicable

References

1. Stanley D, Mason LJ, Mackin KE, Srikhanta YN, Lyras D, Prakash MD, et al. Translocation and dissemination of commensal bacteria in post-stroke infection. Nat Med. 2016;22:1277–84.

2. Miller CM, Behrouz R. Impact of Infection on Stroke Morbidity and Outcomes. Curr Neurol Neurosci Rep. 2016;16:83.

3. Shim R, Wong CH. Ischemia. Immunosuppression and Infection–Tackling the Predicaments of Post-Stroke Complications. Int J Mol Sci. 2016;17.

4. Urra X, Laredo C, Zhao Y, Amaro S, Rudilosso S, Renu A, et al. Neuroanatomical correlates of stroke-associated infection and stroke-induced immunodepression. Brain Behav Immun. 2017;60:142–50.

5. Li M, Li Z, Yao Y, Jin WN, Wood K, Liu Q, et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci U S A. 2017;114:E396–405.

6. Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, et al. Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity. 2017;46:474–87.

7. Winklewski PJ, Radkowski M, Demkow U. Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke. J Neuroinflammation. 2014;11:213.

8. Di Raimondo D, Tuttolomondo A, Butta C, Casuccio A, Giarrusso L, Miceli G, et al. Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise. Int J Clin Pract. 2013;67:1247–53.

9. Di Raimondo D, Tuttolomondo A, Butta C, Miceli S, Licata G, Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des. 2012;18:4385–413.

10. Licata G, Tuttolomondo A, Corrao S, Di Raimondo D, Fernandez P, Caruso C, et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int J Immunopathol Pharmacol. 2006;19:639–46.

11. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke. 2016;47:1817–24.

12. Bessout R, Semont A, Demarquay C, Charcosset A, Benderitter M, Mathieu N. Mesenchymal stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC immunomodulation. Mucosal Immunol. 2014;7:656–69.
13. Bottcher M, Hofmann AD, Bruns H, Haibach M, Loschinski R, Saul D, et al. Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. Stem Cells. 2016;34:516–21.

14. Pianta S, Bonassi SP, Muradore I, Rodrigues MF, Rossi D, Silini A, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev. 2015;11:394–407.

15. Luz-Crawford P, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, et al. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation. Stem Cells. 2016;34:483–92.

16. Cho KA, Lee JK, Kim YH, Park M, Woo SY, Ryu KH. Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell Mol Immunol. 2017.

17. Petri RM, Hackel A, Hahnel K, Dumitru CA, Bruderek K, Flohe SB, et al. Activated Tissue-Resident Mesenchymal Stromal Cells Regulate Natural Killer Cell Immune and Tissue-Regenerative Function. Stem Cell Rep. 2017;9:985–98.

18. Anderson MA, Mann MD, Evans MA, Sparks-Thissen RL. The inner membrane protein YhiM is necessary for Escherichia coli growth at high temperatures and low osmolarity. Arch Microbiol. 2017;199:171–5.

19. Gao C, Qian Y, Huang J, Wang D, Su W, Wang P, et al. A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice. Mol Neurobiol. 2017;54:8348–60.

20. Suda S, Aoki J, Shimoyama T, Suzuki K, Sakamoto Y, Katano T, et al. Stroke-associated infection independently predicts 3-month poor functional outcome and mortality. J Neurol. 2018;265:370–5.

21. Tziomalos K, Ntaios G, Miyakis S, Papanas N, Xanthis A, Agapakis D, et al. Prophylactic antibiotic treatment in severe acute ischemic stroke: the Antimicrobial chemoprophylaxis for Ischemic STrokE In MaceDonla-Thrace Study (ARISTEIDIS). Intern Emerg Med. 2016;11:953–8.

22. Schwarz S. Prophylactic Antibiotic Therapy for Preventing Poststroke Infection. Neurotherapeutics. 2016;13:783–90.

23. Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, et al. Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia - The PREDICT study. J Cereb Blood Flow Metab. 2017;37:3671–82.

24. Mattar P, Bieback K. Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells. Front Immunol. 2015;6:560.

25. Cortinovis M, Casiraghi F, Remuzzi G, Perico N. Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. Curr Opin Organ Transplant. 2015;20:79–85.

26. Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35:766–76.
27. Li X, Xu Z, Bai J, Yang S, Zhao S, Zhang Y, et al. Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Induce T Lymphocyte Apoptosis and Cell Cycle Arrest by Expression of Indoleamine 2, 3-Dioxygenase. Stem Cells Int. 2016;2016:7495135.

28. Zeng SL, Wang LH, Li P, Wang W, Yang J. Mesenchymal stem cells abrogate experimental asthma by altering dendritic cell function. Mol Med Rep. 2015;12:2511–20.

29. Wu J, Ji C, Cao F, Lui H, Xia B, Wang L. Bone marrow mesenchymal stem cells inhibit dendritic cells differentiation and maturation by microRNA-23b. Biosci Rep. 2017;37.

30. Chatterjee D, Marquardt N, Tufa DM, Beauclair G, Low HZ, Hatlapatka T, et al. Role of gamma-secretase in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity. Cell Commun Signal. 2014;12:63.

31. Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L. Immunomodulatory effects of foreskin mesenchymal stromal cells on natural killer cells. J Cell Physiol. 2018;233:5243–54.

32. Chatterjee D, Marquardt N, Tufa DM, Hatlapatka T, Hass R, Kasper C, et al. Human Umbilical Cord-Derived Mesenchymal Stem Cells Utilize Activin-A to Suppress Interferon-gamma Production by Natural Killer Cells. Front Immunol. 2014;5:662.

33. Contreras-Kallens P, Terraza C, Oyarce K, Gajardo T, Campos-Mora M, Barroilhet MT, et al. Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance. Ann N Y Acad Sci. 2018;1417:35–56.

34. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. Bmc Neurol. 2011;11:110.

35. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28:2229–38.

36. Meisel R, Brockers S, Heseler K, Degistirici O, Bülle H, Woite C, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia. 2011;25:648–54.

37. Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphallbeta3, and platelet factor 4. Blood. 2014;123:3166–74.

38. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14:785–92.

39. Carestia A, Kaufman T, Schattner M. Platelets. New Bricks in the Building of Neutrophil Extracellular Traps. Front Immunol. 2016;7:271.

40. Kahn F, Hurley S, Shannon O. Platelets promote bacterial dissemination in a mouse model of streptococcal sepsis. Microbes Infect. 2013;15:669–76.
41. Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, et al. Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016;32:9–15.

42. Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein KP, Hoogendijk AJ, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood. 2016;127:3062–72.

43. Grundler K, Angstwurm M, Hilge R, Baumann P, Annecke T, Crispin A, et al. Platelet mitochondrial membrane depolarization reflects disease severity in patients with sepsis and correlates with clinical outcome. Crit Care. 2014;18:R31.

44. Kraemer BF, Campbell RA, Schwertz H, Franks ZG, Vieira DAA, Grundler K, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood. 2012;120:5014–20.

45. Ouseph MM, Huang Y, Banerjee M, Joshi S, MacDonald L, Zhong Y, et al. Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis. Blood. 2015;126:1224–33.

46. Gyulkhandanyan AV, Allen DJ, Mykhaylov S, Lyubimov E, Ni H, Freedman J, et al. Mitochondrial Inner Membrane Depolarization as a Marker of Platelet Apoptosis: Disclosure of Nonapoptotic Membrane Depolarization. Clin Appl Thromb Hemost. 2017;23:139–47.

47. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5:66–72.

**Figures**

**Figure 1**

The therapeutic effect of ucMSC in MCAO mice. MCAO mice were treated with or without ucMSC. (A) mNSS and (B) lesion area in each group. The data are plotted as the means ± SD. *P < 0.05, n=5 or 3.
Figure 2

ucMSC reduced CD8+ T/NK cells in MCAO mouse brain but not spleen or blood. (A–C) Immunohistochemistry and immunofluorescence of CD8+ T cells and NK cells in the brain. (D) Immunofluorescence of the activated state of microglia. (E–H) Immunofluorescence and flow cytometry of CD8+ T cells and NK cells in the spleen and blood. Scale bar: 100 μm. The data are plotted as the means ± SD. *P < 0.05, n=5.

Figure 3

Expression of pro-inflammatory cytokines IL-6 and TNF-α in mouse plasma. The data are plotted as the means ± SD. *P < 0.05, n=3.
No infective signs were found in the MCAO or ucMSC groups. MCAO mice were treated with or without ucMSC, followed by analysis of (A) white blood cells, (B) lymphocytes, (C) neutrophils, and (D) platelets, as well as (E) HE staining of the brain, lung, liver, and spleen. Scale bar: 100 μm. The data are plotted as the means ± SD. NS, not significant. *P < 0.05, n=5.
Figure 6

Platelet function was maintained by ucMSC treatment in vivo. MCAO mice were treated with or without ucMSCs in the presence or absence of Escherichia coli. (A) Numbers of platelets. (B) Levels of autophagy marker LC3-II and apoptosis markers Bcl-2 and Bcl-xL. Platelet (C) mitochondrial membrane potential (MMP) and (D) ATP levels. The data are plotted as the means ± SD. *P < 0.05, n=5.
Antimicrobial activity of platelets was enhanced by ucMSC. Growth rate of Escherichia coli in Luria-Bertani medium co-cultured with or without platelets in the presence or absence of ucMSC. The data are plotted as the means ± SD. **P < 0.01, *P < 0.05, n=5.